Novel adjuvants for B cell immune responses

Current Opinion in HIV and AIDS

Volumn 4, Issue 5, 2009, Pages 441-446

  Loré, Karin ^a,b   Hedestam, Gunilla B Karlsson ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Adjuvant; Antibody responses; B cells; HIV 1; Vaccine

Indexed keywords

ADJUVANT; ALPHA GALACTOSYLCERAMIDE; ALUMINUM HYDROXIDE; AS 03; AS 04; CRYOPYRIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIBODY AFFINITY; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; LONG TERM EXPOSURE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; HIV ANTIBODIES; HIV-1; HUMANS;

EID: 69549119958     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832da082     Document Type: Review

References (69)

1. Hilleman MR. Six decades of vaccine development: a personal history. Nat Med 1998; 4 (5 Suppl):507-514.
2. McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178-180. (Pubitemid 14132908)
3. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to17 months of age. N Engl J Med 2008;359:2521-2532.
4. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765. (Pubitemid 39488060)
5. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-1702.
6. Vreden SG, Verhave JP, Oettinger T, et al. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 1991; 45:533-538.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-589. This article describes important results from a human clinical trial that demonstrated the dose-sparing effect of an adjuvant on a prototype pandemic influenza vaccine. (Pubitemid 47247854)
8. Boyle J, Eastman D, Millar C, et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 2007; 25:2541-2544. (Pubitemid 46400928)
9. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236. (Pubitemid 38332116)
10. Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6:143-155.
11. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
12. Montefiori D, Sattentau Q, Flores J, et al. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007; 4:e348.
13. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-517. (Pubitemid 46925379)
14. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines 2007; 6:673-684.
15. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11 (4 Suppl):S63-S68. (Pubitemid 40562305)
16. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849-863. (Pubitemid 43261457)
17. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30:23-32.
18. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340-348.
19. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection [see comment]. J Infect Dis 2005; 191:654-665.
20. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671. (Pubitemid 44901996)
21. Eisenbarth S, Colegio OR, O'Connor W Jr, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-1126. This study identifies Nalp3, a member of the NOD-like pattern recognition receptor family, as an important component of the inflammasome activated by Alum. Thus, this paper presents an original mechanism by which Alum induces its adjuvant effect. (Pubitemid 351871731)
22. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869-882. This study demonstrates that release of endogenous uric acid and subsequent activation of inflammatory dendritic cells is essential for the adjuvant effect of Alum. (Pubitemid 351549884)
23. Seubert A, Monacl E, Pizza M, et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractant and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180: 5402-5412.
24. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241. (Pubitemid 43372104)
25. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in nonelderly and elderly adults. PLoS ONE 2009; 4:e4384.
26. Barnett SW, Srivastava IK, Kan E, et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008; 22:339-348. In this study, systemic immunization with an Env protein in adjuvant stimulated sterilizing protection against a mucosal challenge with a homologous SHIV-SF162P4 virus.
27. Vajdy M, Singh M, Kazzaz J, et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 2004; 20:1269-1281. (Pubitemid 39557877)
28. Forsell MN, Dey B, Morner A, et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog 2008; 4:e1000171.
29. Li Y, Svehla K, Mathy NL, et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006; 80:1414-1426. (Pubitemid 43134099)
30. Morner A, Douagi I, Forsell MN, et al. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 2009; 83:540-551. This study evaluates binding and neutralizing antibody responses as well as T-cell responses after inoculation of soluble Env trimers in GSK adjuvant system AS01B in nonhuman primates.
31. Voss G, Manson K, Montefiori D, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003; 77:1049-1058. (Pubitemid 36055526)
32. Ishii KJ, Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007; 27:363-371. (Pubitemid 46906656)
33. Heer AK, Shamshiev A, Donda A, et al. TLR signaling fine-tunes antiinfluenza B cell responses without regulating effector T cell responses. J Immunol 2007; 178:2182-2191. (Pubitemid 46233416)
34. Guay HM, Andreyeva TA, Garcea RL, et al. MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol 2007; 178:5124-5131.
35. Browne EP, Littman DR. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog 2009; 5:e1000298.
36. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314:1936-1938. (Pubitemid 46026117)
37. Hidmark AS, Nordstrom EK, Dosenovic P, et al. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol 2006; 80:7100-7110. (Pubitemid 44025206)
38. Delale T, Paquin A, Asselin-Paturel C, et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 2005; 175:6723-6732. (Pubitemid 41598916)
39. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589:1-13.
40. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004; 101:15440-15445.
41. Huleatt JW, Jacobs AR, Tang J, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25:763-775. (Pubitemid 44856106)
42. Nempont C, Cayet D, Rumbo M, et al. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 2008; 181:2036-2043. This study reports that the TLR5 agonist flagellin provides adjuvant effect when fused to an antigen of interest. The study highlights that without deletion of the immunodominant hypervariable region of flagellin, neutralizing flagellin-specific antibodies are abundantly produced compromising antibody responses against the target antigen.
43. Douagi I, Gujer C, Sundling C, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 2009; 182:1991-2001. This study presents a side-by-side comparison of TLR3, 7/8 and 9 ligands for their ability to stimulate B-cell proliferation, differentiation and antibody production using B cells cultured in vitro in the presence or absence of purified myeloid and plasmacytoid dendritic cells.
44. Wille-Reece U, Flynn BJ, Lore K, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005; 102:15190-15194. (Pubitemid 41513357)
45. Riedl K, Riedl R, von Gabain A, et al. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 2008; 26:3461-3468.
46. Schellack C, Prinz K, Egyed A, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006; 24:5461-5472. (Pubitemid 43831376)
47. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-484. (Pubitemid 44136959)
48. Rothenfusser S, Tuma E, Wagner M, et al. Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther 2003; 5:98-106. (Pubitemid 36626448)
49. Bekeredjian-Ding IB, Wagner M, Hornung V, et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005; 174:4043-4050. (Pubitemid 40395980)
50. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9- ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 2009; 113:3969-3977. This study demonstrates that beads linked to protein antigen and CpG ODN promote proliferation and differentiation of B cells in a BCR-dependent manner, thus leading to TLR9 stimulation selectively in antigen-specific B cells.
51. Malherbe L, Mark L, Fazilleau N, et al. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28:698-709. This study shows that adjuvants can modify TCR-based selection thresholds and influence the clonal composition of T helper cells after inoculation with protein antigens.
52. Schnurr M, Orban M, Robson NC, et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 2009; 182:1253-1259.
53. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761-772.
54. Barral P, Eckl-Dorna J, Harwood NE, et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci U S A 2008; 105:8345-8350. This study demonstrates that iNKT cells activated through CD1d-restricted presentation of α-GalCer promote B-cell proliferation, differentiation and production of class-switched antibodies. (Pubitemid 351904758)
55. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9:28-38.
56. Leadbetter EA, Brigl M, Illarionov P, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A 2008; 105:8339-8344. (Pubitemid 351904757)
57. Sundling C, Schon K, Morner A, et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 2008; 89 (Pt 12):2954-2964.
58. Johnson RP, Desrosiers RC. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 1998; 10:436-443. (Pubitemid 28393827)
59. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7:19-23.
60. Jia B, Ng SK, DeGottardi MQ, et al. Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac) 239. PLoS Pathog 2009; 5:e1000272.
61. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640. This comprehensive study of anti-Env antibodies isolated from chronically infected HIV-1 individuals demonstrates a high degree of affinity maturation compared with the total IgG pool.
62. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-424. The immune-activation profile of the successful yellow fever virus vaccine was characterized in this study, which shows that multiple signalling pathways are activated by this vaccine.
63. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.
64. Kobiyama K, Takeshita F, Ishii KJ, et al. A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J Immunol 2009; 182:1593-1601. This study demonstrates that a peptide derived from IPS-1, a cytosolic signaling molecule involved in the type I interferon induction pathway, exerted adjuvant activity when fused with the transduction domain of Tat to facilitate transport from the extracellular to the intracellular environment.
65. Kumar KA, Sano G, Boscardin S, et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006; 444:937-940. (Pubitemid 46025007)
66. Junt T, Moseman EA, Iannacone M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007; 450:110-114. This paper investigates the fate of virus-sized antigens, showing that subcapsular sinus macrophages play a role in transport and presentation of virus particles to B cells. (Pubitemid 350070574)
67. Scheerlinck JP, Greenwood DL. Particulate delivery systems for animal vaccines. Methods 2006; 40:118-124. (Pubitemid 44415503)
68. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40:60-65.
69. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-6851.